Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Genetic disease company BridgeBio Pharma has launched a subsidiary called Fortify Therapeutics with an initial $20 million in funds and about $40 million more in potential future payments. Fortify will develop a set of succinate prodrug compounds that BridgeBio licensed from NeuroVive to treat a vision loss disease called Leber hereditary optic neuropathy. Fortify is the third subsidiary that BridgeBio has announced in just over a week.
This article has been sent to the following recipient: